74467-03-1

Basic information

• Product Name: Benzenecarboximidoyl chloride, N-hydroxy-2-methyl-
• CAS NO: 74467-03-1
• Molecular Formula: C8H8ClNO
• Molecular Weight: 169.611
• Mol File: 74467-03-1.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Benzenecarboximidoyl chloride, N-hydroxy-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenecarboximidoyl chloride, N-hydroxy-2-methyl-(74467-03-1)
• EPA Substance Registry System: Benzenecarboximidoyl chloride, N-hydroxy-2-methyl-(74467-03-1)

Safety Data

• Hazardous Substances Data: 74467-03-1(Hazardous Substances Data)

Upstream product

• 89-95-2 2-methyl-benzyl alcohol 
• 529-20-4 2-methylphenyl aldehyde 
• 14683-79-5 salicylaldoxime 

Downstream Products

• 91569-58-3 5-Methyl-4-carboxy-3-o-tolyl-isoxazol 
• 617-07-2 N,N'-bis(2-methylphenyl)urea 
• 65349-23-7 3-(2-methylphenyl)-5-phenylisoxazole 

Relevant articles and documents

Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors

α-Glucosidase inhibition is a valid approach for controlling hyperglycemia in diabetes. In the current study, new molecules as a hybrid of isoxazole and dibenzazepine scaffolds were designed, based on their literature as antidiabetic agents. For this, a series of dibenzazepine-linked isoxazoles (33–54) was prepared using Nitrile oxide-Alkyne cycloaddition (NOAC) reaction, and evaluated for their α-glucosidase inhibitory activities to explore new hits for treatment of diabetes. Most of the compounds showed potent inhibitory potency against α-glucosidase (EC 3.2.1.20) enzyme (IC50 = 35.62 ± 1.48 to 333.30 ± 1.67 μM) using acarbose as a reference drug (IC50 = 875.75 ± 2.08 μM). Structure-activity relationship, kinetics and molecular docking studies of active isoxazoles were also determined to study enzyme-inhibitor interactions. Compounds 33, 40, 41, 46, 48–50, and 54 showed binding interactions with critical amino acid residues of α-glucosidase enzyme, such as Lys156, Ser157, Asp242, and Gln353.

Design, synthesis, and in vitro evaluation of novel triazole analogues featuring isoxazole moieties as antifungal agents

In order to develop novel antifungal agents, based on our previous work, a series of (2R,3R)-3-((3-substitutied-isoxazol-5-yl)methoxy)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol (a1-a26) were designed and synthesized. All of the compounds exhibited good in vitro antifungal activities against eight human pathogenic fungi. Among them, compound a6 showed excellent inhibitory activity against Candida albicans and Candida parasilosis with MIC80 values of 0.0313 μg/mL. In addition, compounds a6, a9, a12, a13 and a14 exhibited moderate inhibitory activities against fluconazole-resistant isolates with MIC80 values ranging from 8 μg/mL to 16 μg/mL. Furthermore, compounds a6, a12 and a23 exhibited low inhibition profiles for CYP3A4. Clear SARs were analyzed, and the molecular docking experiment was carried out to further investigate the relationship between a6 and the target enzyme CYP51.

Synthesis of Tricyclic Isoxazoles via Sequential [3+2] Dipolar Cycloaddition and Palladium-Catalyzed Intramolecular Arylation Reactions

An efficient synthetic route to tricyclic isoxazoles via sequential copper-catalyzed 1,3-dipolar cycloaddition and palladium-catalyzed intramolecular arylation of isoxazoles is described. Based on these reactions, a convenient one-pot synthesis of the tri